LONDON, United Kingdom, May 20, 2026
GSK has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved an expanded indication for Arexvy, the company’s respiratory syncytial virus (RSV) vaccine, extending eligibility to adults aged 18 to 49 years who are at increased risk for severe RSV disease. The approval makes Arexvy the first RSV vaccine approved in Japan for all at-risk adults, including younger adults living with chronic medical conditions and immunocompromised individuals.
The expanded approval represents a major milestone in global RSV prevention efforts and significantly broadens access to preventive respiratory healthcare in Japan. Previously, Arexvy was approved only for adults aged 60 years and older and for adults aged 50–59 considered at increased risk. The updated prescribing information now explicitly includes immunocompromised patients, helping physicians identify more individuals who may benefit from RSV vaccination.
Expanded Approval Addresses Rising RSV Risks in Younger Adults
Respiratory syncytial virus is widely recognized as a serious respiratory pathogen that can cause severe lower respiratory tract disease, hospitalization, cardiovascular complications, and death in vulnerable adult populations. Although RSV is often associated with infants and elderly individuals, healthcare experts increasingly recognize that younger adults with chronic diseases may also face substantial risk of severe infection.
According to GSK, millions of adults in Japan aged between 18 and 49 live with chronic conditions including cardiovascular disease, chronic obstructive pulmonary disease (COPD), asthma, diabetes, and immune-compromising disorders that elevate their risk for severe RSV outcomes. RSV infections have also been linked to major adverse cardiovascular events such as heart attacks and stroke, while simultaneously triggering worsening respiratory symptoms in COPD and asthma patients.
Advertisement
The Japanese approval was supported by positive data from a Phase IIIb clinical trial evaluating immune response and safety in adults aged 18–49 at increased risk for RSV disease. Study findings demonstrated a non-inferior immune response compared with adults aged 60 years and older who previously formed the primary target population for the vaccine. Researchers also reported a safety profile consistent with earlier Phase III trials supporting the vaccine’s original approval
The most commonly reported side effects included injection-site pain, fatigue, myalgia, headache, and joint pain, with most adverse events characterized as mild to moderate and temporary in duration.
Arexvy Strengthens GSK’s Global Vaccine Leadership
The latest regulatory expansion further reinforces GSK’s growing leadership in adult respiratory vaccines and infectious disease prevention. Arexvy contains recombinant RSV glycoprotein F stabilized in its prefusion conformation combined with GSK’s proprietary AS01E adjuvant system, designed to strengthen immune response and improve vaccine effectiveness.
GSK executives stated that the approval underscores increasing awareness that RSV can significantly impact adults of all ages with chronic medical conditions. The company believes broader vaccination eligibility may help reduce severe respiratory complications, hospitalization rates, and healthcare burdens associated with RSV outbreaks.
Arexvy has already secured approvals in more than 70 countries for adults aged 60 years and older and in over 60 countries for adults aged 50–59 at increased risk for RSV disease. In the United States, the vaccine is additionally approved for adults aged 18–49 who are at increased risk, while the European Economic Area approved the vaccine for all adults aged 18 years and older.
RSV Prevention Gains Importance in Global Public Health
Healthcare experts continue emphasizing the growing global burden of RSV infections among adults, particularly as aging populations and chronic respiratory diseases continue rising worldwide. RSV affects an estimated 64 million people globally each year and remains one of the leading causes of severe respiratory illness among vulnerable populations.
The expanded Japanese approval also highlights increasing regulatory focus on preventive vaccination strategies aimed at high-risk adult populations rather than only elderly individuals. Public health specialists believe broader RSV immunization could significantly reduce hospitalizations, severe pulmonary complications, and economic healthcare burdens associated with respiratory viral outbreaks.
As governments and healthcare systems prioritize infectious disease prevention following recent global respiratory health challenges, GSK’s expanded Arexvy approval positions the company at the forefront of next-generation adult vaccine innovation and respiratory disease prevention.
Source: GSK press release
